Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Ceftaroline Fosamil
2. Ppi-0903
3. Ppi0903
4. Tak-599
5. Tak599
6. Teflaro
1. Tak-599
2. Schembl1464044
3. Gtpl10899
4. Q409712
5. (6r,7r)-7-((z)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetamido)-3-((4-(1-methylpyridin-1-ium-4-yl)thiazol-2-yl)thio)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
| Molecular Weight | 684.7 g/mol |
|---|---|
| Molecular Formula | C22H21N8O8PS4 |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 10 |
| Exact Mass | 684.01028135 g/mol |
| Monoisotopic Mass | 684.01028135 g/mol |
| Topological Polar Surface Area | 330 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 1210 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J01DI02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23167
Submission : 2009-10-09
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-08-27
Pay. Date : 2014-05-16
DMF Number : 28245
Submission : 2014-06-25
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40900
Submission : 2024-11-29
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Akums Lifescience Ltd. is a research-based, vertically integrated company specializing in the development, manufacturing and sale of APIs and intermediates. Akums has established i...

About the Company : Our herbal ingredients have been clinically studied and shown effective in both animal and human clinical trials. Many of our clinical trials are peer-reviewed, double-blind contro...

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

About the Company : Suzhou Ryway Biotech Co., Ltd. is located in Suzhou of Jiangsu Provice. It is a comprehensive enterprise integrated of product research, manufacturing, marketing and service. There...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Cefazolin is a antibiotic drug, which is currently being evaluated in Phase IV clinical studies for the treatment of staphylococcal infections.
Lead Product(s): Cefazolin,Nafcillin,Ertapenem,Vancomycin Hydrochloride,Daptomycin,Ceftaroline Fosamil
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 29, 2026

Lead Product(s) : Cefazolin, Nafcillin, Ertapenem, Vancomycin Hydrochloride, Daptomycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Details : Cefazolin is a antibiotic drug, which is currently being evaluated in Phase IV clinical studies for the treatment of staphylococcal infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 29, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fractures, Open.
Lead Product(s): Ceftaroline Fosamil,Inapplicable
Therapeutic Area: Orthopedics/Orthopedic Surgery Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Olayemi Osiyemi MD
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 18, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ceftaroline Fosamil,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Olayemi Osiyemi MD
Deal Size : Inapplicable
Deal Type : Inapplicable
Antibiotic Prophylaxis in Open Fractures
Details : Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fractures, Open.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2016

Details:
Ceftriaxone is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Community-Acquired Pneumonia.
Lead Product(s):
Ceftriaxone,Moxifloxacin,Levofloxacin,Piperacillin + Tazobactam,Ceftaroline Fosamil,Amoxicillin Trihydrate,Clavulanic Acid,Azithromycin,
Therapeutic Area: Infections and Infectious Diseases
Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic Sponsor:
Australian and New Zealand Intensive Care Research Centre | Medical Research Institute of New Zealand | Unity Health | Berry Consultants | Global Coalition for Adaptive Research | University of Pittsburgh Medical Center | Intensive Care National Audit & R
Deal Size: Inapplicable
Upfront Cash: Inapplicable
Deal Type: Inapplicable
April 13, 2016

Lead Product(s) : Ceftriaxone, Moxifloxacin, Levofloxacin, Piperacillin + Tazobactam, Ceftaroline Fosamil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Australian and New Zealand Intensive Care Research Centre | Medical Research Institute of New Zealand | Unity Health | Berry Consultants | Global Coalition for Adaptive Research | University of Pittsburgh Medical Center | Intensive Care National Audit & R
Deal Size : Inapplicable
Deal Type : Inapplicable
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Details : Ceftriaxone is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Community-Acquired Pneumonia.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 13, 2016

Details:
Daptomycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bacteremia.
Lead Product(s): Daptomycin,Ceftaroline Fosamil
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 21, 2016

Lead Product(s) : Daptomycin,Ceftaroline Fosamil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
Details : Daptomycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bacteremia.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 21, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Ceftaroline Fosamil,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Basim Asmar
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ceftaroline Fosamil,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Basim Asmar
Deal Size : Inapplicable
Deal Type : Inapplicable
Ceftaroline Diffusion Into Cerebrospinal Fluid of Children
Details : Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2015

Details:
Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Skin Diseases, Infectious.
Lead Product(s): Ceftaroline Fosamil,Vancomycin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Henry Ford Hospital | St. John Providence Health System | Detroit Medical Center | Forest Laboratories
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2015

Lead Product(s) : Ceftaroline Fosamil,Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Henry Ford Hospital | St. John Providence Health System | Detroit Medical Center | Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
Details : Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Skin Diseases, Infectious.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ceftaroline Fosamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neonatal Sepsis.
Lead Product(s): Ceftaroline Fosamil,Ampicillin,Aminoglycoside
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: PRA Health Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 23, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ceftaroline Fosamil,Ampicillin,Aminoglycoside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis
Details : Ceftaroline Fosamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neonatal Sepsis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 23, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ceftaroline Fosamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Osteomyelitis.
Lead Product(s): Ceftaroline Fosamil,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Allergan
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 12, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ceftaroline Fosamil,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ceftaroline Fosamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Osteomyelitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 12, 2015

Details:
Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Surgical Wound Infection.
Lead Product(s): Ceftaroline Fosamil,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Forest Laboratories
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2014

Lead Product(s) : Ceftaroline Fosamil,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection
Details : Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Surgical Wound Infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 03, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ceftaroline Fosamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Skin Diseases, Infectious.
Lead Product(s): Ceftaroline Fosamil,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Forest Laboratories
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ceftaroline Fosamil,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ceftaroline Fosamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Skin Diseases, Infectious.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2014

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
03 Nov 2025
Reply
19 Jan 2024
Reply
23 Aug 2023
Reply
15 Sep 2022
Reply
23 Aug 2022
Reply
18 Jun 2022
Reply
29 Dec 2021
Reply
07 Oct 2021
Reply
19 Mar 2021
Reply
10 Feb 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
12
PharmaCompass offers a list of Ceftaroline Fosamil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ceftaroline Fosamil manufacturer or Ceftaroline Fosamil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ceftaroline Fosamil manufacturer or Ceftaroline Fosamil supplier.
A Ceftaroline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ceftaroline, including repackagers and relabelers. The FDA regulates Ceftaroline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ceftaroline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ceftaroline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Ceftaroline supplier is an individual or a company that provides Ceftaroline active pharmaceutical ingredient (API) or Ceftaroline finished formulations upon request. The Ceftaroline suppliers may include Ceftaroline API manufacturers, exporters, distributors and traders.
click here to find a list of Ceftaroline suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Ceftaroline DMF (Drug Master File) is a document detailing the whole manufacturing process of Ceftaroline active pharmaceutical ingredient (API) in detail. Different forms of Ceftaroline DMFs exist exist since differing nations have different regulations, such as Ceftaroline USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ceftaroline DMF submitted to regulatory agencies in the US is known as a USDMF. Ceftaroline USDMF includes data on Ceftaroline's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ceftaroline USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ceftaroline suppliers with USDMF on PharmaCompass.
Ceftaroline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ceftaroline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ceftaroline GMP manufacturer or Ceftaroline GMP API supplier for your needs.
A Ceftaroline CoA (Certificate of Analysis) is a formal document that attests to Ceftaroline's compliance with Ceftaroline specifications and serves as a tool for batch-level quality control.
Ceftaroline CoA mostly includes findings from lab analyses of a specific batch. For each Ceftaroline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ceftaroline may be tested according to a variety of international standards, such as European Pharmacopoeia (Ceftaroline EP), Ceftaroline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ceftaroline USP).